Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q8WWZ4

UPID:
ABCAA_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q8WWZ4; C9JZH2; C9K035; Q6PIQ6; Q7Z2I9; Q7Z7P7; Q86TD2

BACKGROUND:
The ATP-binding cassette sub-family A member 10, known as ABCA10, is implicated as a probable transporter with a significant role in the regulation of macrophage lipid transport and homeostasis. ABCA10 belongs to the extensive family of ABC transporters, crucial for transporting a variety of substances across membranes in the body.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of ATP-binding cassette sub-family A member 10 offers a promising avenue for the development of novel therapeutic strategies. Given its critical role in lipid transport and homeostasis, ABCA10 could be a valuable target in treating disorders associated with lipid dysregulation.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.